バイオテクノロジー受託製造の世界市場：産業規模、シェア、動向、機会、予測 - サービス別、タイプ別、事業規模別、治療領域別、地域別、競合、2019～2029年

世界のバイオテクノロジー受託製造の市場規模は、2023年に221億5,000万米ドルに達し、2029年までの予測期間中にCAGR 7.48%で安定した成長が予測されています。

世界のバイオテクノロジー受託製造市場は、バイオテクノロジー産業において極めて重要な役割を果たすダイナミックで急速に発展している分野です。この市場には、主にバイオ医薬品およびバイオテクノロジー企業向けの、広範な製造受託機関（CMO）およびサービスが含まれます。この市場を牽引しているのは、モノクローナル抗体、ワクチン、遺伝子治療、細胞ベース治療など、専門的な知識と製造設備を必要とするバイオ医薬品に対する需要の高まりです。

世界のバイオテクノロジー受託製造市場の主な促進要因は、バイオ医薬品の複雑性の高まりと、コスト効率と柔軟性に優れた製造ソリューションへのニーズです。多くのバイオテクノロジー企業は、CMOに製造の必要性をアウトソーシングすることで、CMOの大規模生産、品質管理、法規制遵守に関する専門知識を活用しながら研究開発に専念することを望んでいます。同市場は、バイオシミラーの重要性の高まりと、市場の需要を満たすための迅速なスケールアップ生産の必要性から影響を受けています。製造受託機関は、バイオシミラーの開発・製造においてコスト効率と拡張性の高いソリューションを提供し、生物学的製剤をより安価に入手できるようにします。世界の市場情勢は、多数のCMOが市場シェアを争っており、競争が激しいのが特徴です。これらの企業は、細胞株開発、プロセス開発、製造、充填仕上げ作業など、さまざまなサービスを提供しています。バイオプロセス技術の進歩とシングルユースシステムへのシフトが市場の将来を形成しており、製造の効率化と環境への配慮が進んでいます。

主な市場促進要因

バイオ医薬品需要の増加

バイオ医薬品の複雑化

バイオシミラー市場の成長

主な市場課題

品質と安全性への懸念

コストに関する懸念

主な市場動向

バイオプロセス技術の進歩

個別化医療と細胞治療

目次

第1章 概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 地域別

第5章 アジア太平洋のバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのバイオテクノロジー受託製造の市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別
  • タイプ別
  • 事業規模別
  • 治療領域別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のバイオテクノロジー受託製造市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• 供給企業の力
• 顧客の購買力
• 代替品の脅威

第14章 競合情勢

• Lonza Group Ltd.
• Thermo Fisher Scientific, Inc.
• Wuxi Biologics Co., Ltd.
• Catalent, Inc.
• Samsung Biologics Co., Ltd.
• Boehringer Ingelheim International GmbH
• Fujifilm Holdings Corporation
• Abbvie Inc.
• Eurofins Scientific SE
• Genscript Biotech Corporation

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Biotechnology Contract Manufacturing Market was valued at USD 22.15 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.48% through 2029. The Global Biotechnology Contract Manufacturing Market is a dynamic and rapidly evolving sector that plays a pivotal role in the biotechnology industry. It encompasses a wide range of contract manufacturing organizations (CMOs) and services, primarily catering to biopharmaceutical and biotechnology companies. This market is driven by the increasing demand for biopharmaceutical products, such as monoclonal antibodies, vaccines, gene therapies, and cell-based therapies, which require specialized expertise and manufacturing facilities.

The key drivers of the global biotechnology contract manufacturing market is the rising complexity of biopharmaceuticals and the need for cost-effective and flexible manufacturing solutions. Many biotech companies prefer to outsource their manufacturing needs to CMOs, allowing them to focus on research and development while leveraging the CMO's expertise in large-scale production, quality control, and regulatory compliance. The market is influenced by the growing importance of biosimilars and the need for rapid scale-up production to meet market demand. Contract manufacturing organizations offer a cost-efficient and scalable solution for biosimilar development and manufacturing, enabling more affordable access to biologic therapies. The global biotechnology contract manufacturing market is characterized by a highly competitive landscape, with numerous CMOs vying for market share. These companies offer a range of services, including cell line development, process development, manufacturing, and fill-finish operations. Advancements in bioprocessing technologies and a shift toward single-use systems are shaping the market's future, making manufacturing more efficient and environmentally friendly.

Key Market Drivers

Increasing Demand for Biopharmaceuticals

The increasing demand for biopharmaceuticals is a pivotal driver behind the robust growth of the Global Biotechnology Contract Manufacturing Market. Biopharmaceuticals, including monoclonal antibodies, gene therapies, vaccines, and cell-based therapies, have become essential components of modern healthcare, offering innovative and highly effective treatments for a wide range of diseases. This surge in demand is driven by several factors, including the growing prevalence of chronic diseases, the aging global population, and advancements in medical science.

The rise in chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases, has created a substantial need for advanced therapeutic solutions. Biopharmaceuticals, with their ability to target specific disease mechanisms and minimize side effects, are increasingly preferred by both patients and healthcare providers. Biotech companies are under pressure to meet the surging demand for these specialized treatments. The global population is aging, resulting in a greater prevalence of age-related conditions and chronic illnesses. As a result, the need for biopharmaceutical interventions that address these healthcare challenges continues to grow. As life expectancies increase, there is an expanding market for therapies that enhance the quality of life and extend healthy aging.

The continuous scientific and technological advancements are driving the development of new biopharmaceuticals. These breakthroughs often target previously untreatable conditions or provide more effective alternatives to existing treatments. As innovative therapies make their way through clinical trials and regulatory approvals, the demand for contract manufacturing services to meet production requirements intensifies. The escalating demand for biopharmaceuticals directly impacts the biotechnology contract manufacturing market, as biotech companies increasingly turn to contract manufacturing organizations (CMOs) for their specialized manufacturing expertise and facilities. CMOs play a pivotal role in meeting the production needs of biopharmaceutical companies, offering cost-effective and scalable solutions to accommodate the surging demand.

Increasing Complexity of Biopharmaceuticals

The increasing complexity of biopharmaceuticals is a pivotal factor driving the growth of the Global Biotechnology Contract Manufacturing Market. Biopharmaceuticals, including monoclonal antibodies, gene therapies, vaccines, and cell-based therapies, have become increasingly intricate in their composition and manufacturing processes. This growing complexity presents biotech companies with significant challenges, prompting them to turn to contract manufacturing organizations (CMOs) for their specialized expertise and state-of-the-art facilities.

One key aspect of biopharmaceutical complexity is the intricate nature of these products. They often involve complex protein structures, delicate biologic materials, and highly specific manufacturing requirements. The development and production of biopharmaceuticals demand specialized knowledge and capabilities that many biotech companies may not possess in-house. CMOs are uniquely positioned to meet these challenges, as they have dedicated teams of experts who understand the intricacies of biopharmaceutical production.

The regulatory landscape for biopharmaceuticals is increasingly stringent. Regulatory agencies, such as the FDA and EMA, have raised the bar for quality and safety standards. Biotech companies must adhere to these rigorous regulatory requirements to bring their products to market. CMOs, with their extensive experience and expertise in navigating the regulatory framework, provide a valuable resource for ensuring compliance with these demanding standards. As biopharmaceuticals continue to advance in complexity, the need for advanced manufacturing facilities equipped with cutting-edge technology is more critical than ever. CMOs invest in state-of-the-art infrastructure to meet the evolving needs of biotech companies. These facilities are designed to handle complex production processes, ensuring that the final products meet the highest quality standards.

In the biotechnology contract manufacturing market, the increasing complexity of biopharmaceuticals has made CMOs indispensable partners for biotech firms seeking to bring innovative therapies to market. CMOs offer comprehensive solutions, from cell line development and process optimization to large-scale production and fill-finish operations. Their ability to handle the complexities of biopharmaceutical manufacturing efficiently and effectively not only accelerates the time to market for new therapies but also ensures product quality and regulatory compliance.

Biosimilars Market Growth

The rapid growth of the biosimilars market is a significant driver behind the expanding Global Biotechnology Contract Manufacturing Market. Biosimilars are biologic products that are highly similar to approved reference biologics, offering a more cost-effective alternative to their originator counterparts. The biosimilars market has gained substantial momentum in recent years due to several factors, and this growth has had a profound impact on the contract manufacturing landscape.

One of the primary drivers of the biosimilars market growth is the impending expiry of patents for many originator biologics. As these patents expire, it opens the door for competition from biosimilar manufacturers. Biotech companies and pharmaceutical firms are seizing the opportunity to enter the biosimilars market, which necessitates specialized manufacturing capabilities. Contract Manufacturing Organizations (CMOs) have established themselves as key players in this space, providing the expertise and infrastructure needed to develop and produce biosimilar products efficiently and cost-effectively.

Biosimilars offer a more affordable alternative to expensive originator biologics, making them an attractive option for healthcare systems and patients alike. As governments and healthcare providers worldwide seek ways to contain rising healthcare costs, biosimilars play a vital role in providing access to high-quality biologic therapies at lower prices. The cost advantages of biosimilars have led to increased market demand, further driving the need for contract manufacturing services to scale up production and meet this demand. Another factor contributing to the growth of the biosimilars market is the increasing recognition and acceptance of these products by regulatory agencies. Regulatory pathways for biosimilar approval have become more well-defined, and agencies such as the FDA and EMA have implemented clear guidelines for biosimilar development and approval. This regulatory clarity has encouraged investment in biosimilar development and manufacturing, creating opportunities for CMOs to support the development of these biologic products.

The convergence of these factors has made biosimilars a thriving and competitive segment of the pharmaceutical industry. CMOs are instrumental in enabling biotech companies and pharmaceutical firms to enter the biosimilars market quickly and efficiently, providing them with specialized manufacturing services, regulatory expertise, and scalable facilities.

Key Market Challenges

Quality and Safety Concerns

Biopharmaceuticals are subject to stringent regulatory requirements imposed by health authorities worldwide, such as the FDA in the United States and the EMA in Europe. To meet these standards, contract manufacturing organizations (CMOs) must establish and maintain robust quality control systems, extensive documentation, and validation processes. Any deviations from these regulatory requirements can result in manufacturing delays, recalls, or even the rejection of product batches, posing significant challenges to CMOs. Maintaining consistency in biopharmaceutical manufacturing is a formidable task, as these products often comprise highly complex, large molecules with precise structures. Even minor deviations in manufacturing parameters, raw materials, or environmental conditions can lead to variations between production batches. To ensure batch-to-batch consistency, CMOs must invest in advanced analytical techniques, process controls, and extensive testing, all of which demand substantial resources.

Biopharmaceutical production relies on specialized equipment and facilities, all of which must be validated to ensure they consistently meet predetermined quality and safety standards. Regular validation processes can be time-consuming and resource-intensive, as they involve rigorous testing, calibration, and documentation of equipment and facility performance. This ongoing validation effort is crucial to maintain quality control but can pose a challenge in terms of operational efficiency and cost management. Biopharmaceutical products necessitate extensive analytical testing to verify their identity, purity, and potency. CMOs need to employ a wide range of analytical techniques, such as mass spectrometry, chromatography, and bioassays, to assess product quality comprehensively. Implementing and maintaining these analytical techniques and the personnel required to operate them represent both a significant investment and a challenge for CMOs.

Cost Concerns

Biopharmaceutical manufacturing facilities require substantial capital investments. Setting up and maintaining state-of-the-art facilities, equipped with specialized equipment and infrastructure, demands significant financial resources. For smaller or emerging contract manufacturing organizations (CMOs), the initial capital outlay can be a major barrier to entry and expansion. Beyond the initial capital expenditure, CMOs face ongoing operational expenses that include personnel, utilities, maintenance, and regulatory compliance costs. Maintaining highly trained staff and adhering to strict regulatory standards adds to the cost of operations. The need to continually invest in employee training and development, infrastructure upgrades, and compliance measures puts pressure on operating budgets.

Biopharmaceutical manufacturing demands rigorous quality control and assurance measures, necessitating advanced equipment, testing, and validation processes. The costs associated with these quality control efforts are significant and are essential to ensure product safety and compliance with regulatory standards. CMOs must allocate substantial resources to maintain the highest quality standards. The biotechnology contract manufacturing market is subject to stringent regulatory requirements, and ensuring compliance is a resource-intensive process. CMOs must invest in personnel and technology to meet these evolving regulatory standards, which may involve extensive documentation, validation, and auditing. The cost of regulatory compliance can be substantial and continues to rise as regulatory agencies refine their guidelines.

Raw materials used in biopharmaceutical production, such as cell lines, media, and excipients, can be costly. Managing the quality and consistency of these materials and establishing secure supply chains are essential for maintaining product quality. CMOs must negotiate with suppliers and implement quality control measures to ensure that raw materials meet the required standards, which can have financial implications.

Key Market Trends

Advancements in Bioprocessing Technologies

Advancements in bioprocessing technologies have emerged as a significant driving force behind the growth of the Global Biotechnology Contract Manufacturing Market. These innovations in bioprocessing have revolutionized the way biopharmaceuticals are developed, produced, and brought to market, offering a range of benefits that enhance efficiency, scalability, and sustainability within the industry.

One of the key advancements in bioprocessing technologies is the widespread adoption of single-use systems. Traditionally, stainless steel equipment was used in biopharmaceutical manufacturing, but single-use systems have rapidly gained prominence. These disposable components, such as bioreactors, tubing, and filters, offer several advantages. They reduce the risk of cross-contamination, eliminate the need for complex cleaning and validation procedures, and enhance the flexibility of manufacturing operations. CMOs have embraced single-use systems, allowing them to quickly adapt to varying production requirements, reduce downtime between product changeovers, and ultimately lower operating costs.

Continuous bioprocessing is another innovative trend within the industry. Unlike traditional batch processing, continuous bioprocessing involves the uninterrupted flow of materials through a production system. This approach offers several benefits, including increased efficiency, reduced production time, and improved product consistency. CMOs that implement continuous bioprocessing can optimize their manufacturing operations, leading to cost savings and improved responsiveness to market demands.

Advancements in analytical techniques and process monitoring have significantly improved product quality and consistency. The introduction of sophisticated tools, such as mass spectrometry, high-throughput analytics, and real-time monitoring systems, has enabled CMOs to assess product attributes with higher precision and speed. This level of analytical sophistication helps identify and address deviations in real-time, ensuring that the final products meet the highest quality standards.

These advancements in bioprocessing technologies are particularly beneficial in the context of the biotechnology contract manufacturing market. Contract manufacturing organizations (CMOs) are quick to adopt these innovations, equipping their facilities with state-of-the-art, cutting-edge equipment. This ensures they can meet the evolving demands of biotech companies while remaining cost-effective and environmentally sustainable.

Personalized Medicine and Cell Therapies

The advent of personalized medicine and cell therapies has emerged as a potent force propelling the Global Biotechnology Contract Manufacturing Market. Personalized medicine, characterized by therapies tailored to an individual's unique genetic makeup, and cell therapies, which utilize a patient's own cells to treat various medical conditions, represent groundbreaking advancements in the biopharmaceutical industry. These innovative approaches to healthcare have significantly contributed to the demand for specialized contract manufacturing services.

Personalized medicine leverages genetic information and diagnostic tools to create targeted therapies that are more effective and produce fewer adverse effects. The emergence of companion diagnostics, which aid in selecting the most suitable treatment for individual patients, has fostered the growth of personalized medicine. This trend has led to an increased need for specialized contract manufacturing services to produce these highly individualized therapeutic agents. Contract Manufacturing Organizations (CMOs) are vital partners in the production of personalized medicines, as they offer the expertise and infrastructure necessary to develop and manufacture these highly customized treatments efficiently.

Cell therapies, on the other hand, utilize a patient's own cells, such as immune cells or stem cells, to treat diseases like cancer, autoimmune disorders, and neurological conditions. The promise of cell therapies lies in their ability to precisely target and repair damaged or malfunctioning cells, offering new hope for previously untreatable conditions. The complex and individualized nature of cell therapies demands specialized manufacturing capabilities that CMOs can provide. These therapies require highly controlled environments, skilled personnel, and state-of-the-art facilities to ensure product quality and regulatory compliance.

The growth of the personalized medicine and cell therapy markets is driving the demand for contract manufacturing services, as many biotech companies lack the specialized facilities and expertise needed for these innovative treatment modalities. CMOs are essential partners in bridging this gap, offering a range of services, from process development and scale-up to large-scale manufacturing, to meet the requirements of personalized medicine and cell therapies.

Segmental Insights

Service Insights

Based on Service, Manufacturing emerged as the fastest growing segment in the Global Biotechnology Contract Manufacturing Market in 2023. Manufacturing is at the core of the drug development process. It involves the production of biopharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and other innovative treatments. Manufacturing services encompass cell line development, fermentation or cell culture, downstream processing, and purification, among other critical steps. As the essential phase of drug production, it represents the foundation upon which all other services build. The intricacies of biopharmaceutical manufacturing require highly specialized expertise and state-of-the-art facilities. Biotech companies, particularly smaller and emerging firms, often lack the necessary resources and infrastructure for in-house production. Contract Manufacturing Organizations (CMOs) are equipped with the required knowledge, skills, and facilities to meet the complex manufacturing demands of biopharmaceuticals. They offer clients access to advanced technology and specialized personnel, which is instrumental in achieving efficient and high-quality production.

Type Insights

Based on Type, Biologic Drug Substance Manufacturing emerged as the dominant segment in the Global Biotechnology Contract Manufacturing Market in 2023. Biologic drug substance manufacturing is a foundational step in the production of biopharmaceuticals. It involves the production of the active ingredients or the therapeutic molecules that constitute the core of biologic drugs. This includes the generation of complex proteins, monoclonal antibodies, vaccines, gene therapies, and other biologic molecules. The drug substance is the primary therapeutic component that drives the efficacy of these treatments, making this stage of production crucial. Biologic drug substance manufacturing is highly complex and requires specialized knowledge and expertise. The production of biologic molecules involves intricate processes, including cell culture, fermentation, purification, and downstream processing. Contract Manufacturing Organizations (CMOs) offering biologic drug substance manufacturing services are equipped with state-of-the-art facilities and experienced personnel who understand the intricacies of these processes, ensuring the efficient and high-quality production of drug substances.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Biotechnology Contract Manufacturing Market in 2023, holding the largest market share. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set stringent standards for biopharmaceutical manufacturing. North American CMOs have experience and a strong track record in navigating complex regulatory landscapes and ensuring compliance with evolving guidelines. This expertise instills confidence in biotech companies, making North American CMOs highly sought after for their regulatory competence. North America consistently invests in biopharmaceutical research and development. This commitment to innovation results in a continuous stream of new drug candidates, including biologics, gene therapies, and vaccines. As these candidates progress through clinical trials and receive regulatory approval, the demand for contract manufacturing services escalates.

Key Market Players

Lonza Group Ltd.

Thermo Fisher Scientific, Inc.

Wuxi Biologics Co., Ltd.

Catalent, Inc.

Samsung Biologics Co., Ltd.

Boehringer Ingelheim International GmbH

Fujifilm Holdings Corporation

Abbvie Inc.

Eurofins Scientific SE

Genscript Biotech Corporation

Report Scope:

In this report, the Global Biotechnology Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biotechnology Contract Manufacturing Market, By Service:

Manufacturing Formulation and Fill-Finish Packaging and Labeling Other services

Biotechnology Contract Manufacturing Market, By Type:

Biologic Drug Substance Manufacturing Biologic Drug Product Manufacturing

Biotechnology Contract Manufacturing Market, By Scale of Operation:

Commercial Operations Clinical Operations

Biotechnology Contract Manufacturing Market, By Therapeutic Area:

Autoimmune Diseases Cardiovascular Diseases Metabolic Diseases Infectious Diseases Neurology Other Therapeutic Areas

Biotechnology Contract Manufacturing Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biotechnology Contract Manufacturing Market.

Available Customizations:

Global Biotechnology Contract Manufacturing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Biotechnology Contract Manufacturing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Other services)
  • 4.2.2. By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing)
  • 4.2.3. By Scale of Operation (Commercial Operations, Clinical Operations)
  • 4.2.4. By Therapeutic Area (Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Other Therapeutic Areas)
  • 4.2.5. By Region
  • 4.2.6. By Company (2023)
• 4.3. Market Map
  • 4.3.1. By Service
  • 4.3.2. By Type
  • 4.3.3. By Scale of Operation
  • 4.3.4. By Therapeutic Area
  • 4.3.5. By Region

5. Asia Pacific Biotechnology Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service
  • 5.2.2. By Type
  • 5.2.3. By Scale of Operation
  • 5.2.4. By Therapeutic Area
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Biotechnology Contract Manufacturing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Service
      • 5.3.1.2.2. By Type
      • 5.3.1.2.3. By Scale of Operation
      • 5.3.1.2.4. By Therapeutic Area
  • 5.3.2. India Biotechnology Contract Manufacturing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Service
      • 5.3.2.2.2. By Type
      • 5.3.2.2.3. By Scale of Operation
      • 5.3.2.2.4. By Therapeutic Area
  • 5.3.3. Australia Biotechnology Contract Manufacturing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Service
      • 5.3.3.2.2. By Type
      • 5.3.3.2.3. By Scale of Operation
      • 5.3.3.2.4. By Therapeutic Area
  • 5.3.4. Japan Biotechnology Contract Manufacturing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Service
      • 5.3.4.2.2. By Type
      • 5.3.4.2.3. By Scale of Operation
      • 5.3.4.2.4. By Therapeutic Area
  • 5.3.5. South Korea Biotechnology Contract Manufacturing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Service
      • 5.3.5.2.2. By Type
      • 5.3.5.2.3. By Scale of Operation
      • 5.3.5.2.4. By Therapeutic Area

6. Europe Biotechnology Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Type
  • 6.2.3. By Scale of Operation
  • 6.2.4. By Therapeutic Area
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Biotechnology Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Scale of Operation
      • 6.3.1.2.4. By Therapeutic Area
  • 6.3.2. Germany Biotechnology Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Scale of Operation
      • 6.3.2.2.4. By Therapeutic Area
  • 6.3.3. Spain Biotechnology Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Scale of Operation
      • 6.3.3.2.4. By Therapeutic Area
  • 6.3.4. Italy Biotechnology Contract Manufacturing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Service
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Scale of Operation
      • 6.3.4.2.4. By Therapeutic Area
  • 6.3.5. United Kingdom Biotechnology Contract Manufacturing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Service
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Scale of Operation
      • 6.3.5.2.4. By Therapeutic Area

7. North America Biotechnology Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Type
  • 7.2.3. By Scale of Operation
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Biotechnology Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Scale of Operation
      • 7.3.1.2.4. By Therapeutic Area
  • 7.3.2. Mexico Biotechnology Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Scale of Operation
      • 7.3.2.2.4. By Therapeutic Area
  • 7.3.3. Canada Biotechnology Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Scale of Operation
      • 7.3.3.2.4. By Therapeutic Area

8. South America Biotechnology Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Type
  • 8.2.3. By Scale of Operation
  • 8.2.4. By Therapeutic Area
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Biotechnology Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Scale of Operation
      • 8.3.1.2.4. By Therapeutic Area
  • 8.3.2. Argentina Biotechnology Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Scale of Operation
      • 8.3.2.2.4. By Therapeutic Area
  • 8.3.3. Colombia Biotechnology Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Scale of Operation
      • 8.3.3.2.4. By Therapeutic Area

9. Middle East and Africa Biotechnology Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Type
  • 9.2.3. By Scale of Operation
  • 9.2.4. By Therapeutic Area
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Biotechnology Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Scale of Operation
      • 9.3.1.2.4. By Therapeutic Area
  • 9.3.2. Saudi Arabia Biotechnology Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Scale of Operation
      • 9.3.2.2.4. By Therapeutic Area
  • 9.3.3. UAE Biotechnology Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Scale of Operation
      • 9.3.3.2.4. By Therapeutic Area

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Biotechnology Contract Manufacturing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Lonza Group Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Thermo Fisher Scientific, Inc.
• 14.3. Wuxi Biologics Co., Ltd.
• 14.4. Catalent, Inc.
• 14.5. Samsung Biologics Co., Ltd.
• 14.6. Boehringer Ingelheim International GmbH
• 14.7. Fujifilm Holdings Corporation
• 14.8. Abbvie Inc.
• 14.9. Eurofins Scientific SE
• 14.10. Genscript Biotech Corporation

15. Strategic Recommendations

16. About Us & Disclaimer